Last month, the FDA warned that immuno-oncology stars from Merck and Roche might actually be hurting some previously untreated bladder cancer patients’ survival chances. And now, it’s followed up by narrowing the drugs’ labels. More: FDA slaps new bladder cancer
read moreBristol-Myers Squibb’s Opdivo is finally under FDA consideration as a therapy for previously untreated lung cancer, but it will still be a while before it can compete in the key market. More: FDA accepts Bristol-Myers' Opdivo-Yervoy app in lung cancer,
read moreAbout two months after England’s cost watchdog decided Roche’s multiple sclerosis star Ocrevus wasn’t cost-effective enough to win reimbursement backing in relapsing forms of the disease, the agency overturned that ruling with one limitation. More: NICE reconsiders and agrees to
read moreShire has won approval to transfer production of an important replacement therapy to a plant in Georgia that it got in its 2016 buyout of Baxalta. More: Shire wins FDA approval to make Gammagard Liquid at new U.S. plant, ramps
read moreDesigned to assess and reward the competencies and potential of pharma marketers and teams, the PharmaTimes Marketer of the Year competition identifies and benchmarks marketing talent within pharma organisations. More: Are you the best at what you do? Source: News
read moreIf the answer is yes, why not show us and everyone else how it’s done by entering PharmaTimes Communications Team of the Year Awards TODAY! More: Can you deliver the results you need to take your customer’s business to the
read more© 1994 - 2026 B.M. Pharmaceuticals